Baveno VI标准与内镜筛查Child-Pugh A级肝硬化高危静脉曲张的成本效益比较
本研究构建分析决策模型,从英国国家卫生服务体系视角,比较Baveno VI标准与内镜筛查Child-Pugh A级肝硬化高危静脉曲张的成本效益,并在加拿大和西班牙重复分析。结果显示Baveno VI标准在所有分析中均具成本效益,每增加一个QALY的增量成本为2081英镑,5年内每例患者增量净货币效益为2808英镑。
要点
- Baveno VI标准在1年、5年和20年时间范围内均为具成本效益的策略。
- 每1000例患者5年内增加0.16个QALY,增量成本326英镑,每增加一个QALY增量成本2081英镑。
- Baveno VI标准在加拿大和西班牙同样具成本效益,确定性及概率敏感性分析支持该结果。
核心结论
- Baveno VI标准与内镜相比具成本效益,基于安全性、适宜性和经济学依据,建议考虑广泛实施。
研究设计与样本
- 构建分析决策模型,从英国国家卫生服务体系视角,比较Baveno VI标准与内镜在Child-Pugh A级肝硬化患者中诊断高危静脉曲张的成本与收益。
- 分析时间范围为1年、5年和20年,使用已发表证据数据填充马尔可夫模型,结局以质量调整生命年(QALY)和避免死亡衡量。
- 使用相关成本输入在加拿大和西班牙重复分析。
主要发现
- Baveno VI标准在所有分析中均具成本效益。
- 每1000例患者5年内增加0.16个QALY,增量成本326英镑(443.41美元),每增加一个QALY增量成本2081英镑(2830美元)。
- Baveno VI标准与内镜相比,5年内每例患者增量净货币效益为2808英镑(3819美元)。
- Baveno VI标准在加拿大和西班牙同样具成本效益,确定性和概率敏感性分析支持这些发现。
临床怎么用
- 原文结论指出Baveno VI标准具成本效益,建议基于安全性、适宜性和经济学依据考虑广泛实施。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Although upper gastrointestinal endoscopy (EGD) remains the gold standard for detecting varices in cirrhosis, the Baveno VI criteria proposed a combination of transient elastography and platelet count that could rule out high-risk varices, therefore sparing the need for an endoscopy, with significant potential cost savings. We performed a cost-effectiveness analysis of the Baveno VI criteria compared with EGD in the diagnosis of high-risk varices in cirrhosis. METHODS: We built an analytical decision model to estimate the cost and benefits of using the Baveno VI criteria compared with EGD in patients with Child-Pugh A cirrhosis. The analysis was performed from the UK National Health Service perspective, over 1, 5, and 20 years. A Markov model was populated with data from published evidence. Outcomes were measured in terms of quality-adjusted life years (QALYs) and avoided deaths. The analyses were repeated for Canada and Spain, using relevant cost inputs. RESULTS: The Baveno VI criteria were cost effective compared with endoscopy in all analyses. For 1000 patients, they produced 0.16 additional QALYs at an incremental cost of £326 ($443.41) over 5 years, resulting in an incremental cost of £2081 ($2830) per additional QALY gained. The incremental net monetary benefit of Baveno VI compared with EGD was £2808 ($3819) over 5 years per patient. Baveno VI criteria also were cost effective in Canada and Spain. Deterministic and probabilistic sensitivity analysis supported these findings. CONCLUSIONS: The findings demonstrate that the Baveno VI criteria are cost effective, suggesting that they should be considered for widespread implementation on the basis of safety, appropriateness, and economic grounds.
引用
- Pizzo E, Avşar TS, Abraldes JG, et al. Cost-Effectiveness of the Baveno VI Criteria Compared With Endoscopy for High-Risk Varices in Patients With Child-Pugh A Cirrhosis. Clin Gastroenterol Hepatol. 2024. PMID: 38777174. doi:10.1016/j.cgh.2024.05.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。